Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNCT19 Following ASCT in Relapsed or Refractory Aggressive B-cell Lymphoma
NCT04690192Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of inaticabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2021; status: completed.
02
Drugs
inaticabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04690192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690192.